WEGOVY
PeakNDASUBCUTANEOUSSOLUTIONPriority Review
Approved
Jun 2021
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
8
Data completeness
3/8 — Basic
Priority Review
Drug data last refreshed 19h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
WEGOVY is a subcutaneous solution approved in 2021 by Novo Nordisk for weight management. The product is currently in peak commercial lifecycle stage. Mechanism of action and specific indications are not disclosed in available data.
Peak14.3 years to LOE
Peak-stage product with established market presence; brand teams typically maintain mid-to-large size with focus on market penetration and managed care strategies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (8)
WEgovy Real World Assessment of Weight Loss in Korea
Started Nov 2025
500 enrolled
Obesity
A Two-year Prospective, Observational Study of Wegovy in Real-world Clinical Practice
Started May 2025
1,250 enrolled
Obesity
A Clinical Study Comparing Semaglutide Injection and Wegovy® for Weight Management in Obese Subjects
Started Mar 2025
408 enrolled
Obesity
A Multicentre, Prospective, Single-arm, Non-interventional Regulatory Post-marketing Surveillance (rPMS) Study to Investigate the Safety and Effectiveness of Wegovy® (Semaglutide) in Patients With Obesity and Patients With Overweight in Routine Clinical Practice in Korea
Started Nov 2024
840 enrolled
Obesity and Overweight
Special Use - Results Surveillance on Long-term Use With Wegovy®
Started Jun 2024
1,071 enrolled
Obesity
Worked on WEGOVY at Novo Nordisk? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.